Roberto R Rosato

Roberto R Rosato

Auto-generated profile, based on publicly available information

Roberto R Rosato

Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 February 2002
Verified
Journal Article
Closed access
RRRoberto R Rosato
Roberto R Rosato
JAJorge A Almenara
Jorge A Almenara
LCLeanne Cartee
Leanne Cartee
VBVicki Betts
Vicki Betts
SCSrikumar P Chellappan
Srikumar P Chellappan
SGSteven Grant
Steven Grant

1 January 2004 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
RRRoberto R Rosato
Roberto R Rosato
SGSteven Grant
Steven Grant
In addition to a variety of other novel agents, interest in histone deacetylase inhibitors (HDACIs) as antineoplastic drugs has recently accelerated and increasing numbers of these compounds have entered clinical trials in humans. HDACIs represent a prototype of molecularly targeted agents that perturb signal transduction, cell cycle-regulatory and survival-related pathways. Newer generation HDACIs have been introduced into the clinical arena that are considerably more potent on a molar basis than their predecessors and are beginning to show early evidence of activity, particularly in hematopoietic malignancies. In addition, there is an increasing appreciation of the fact that HDACIs may act through mechanisms other than induction of histone acetylation and, as in the case of other molecularly-targeted agents, it is conceivable that the ultimate role of HDACIs in cancer therapy will be as modulators of apoptosis induced by other cytotoxic agents. One particularly promising strategy involves attempts to combine HDACIs with other novel agents to promote tumour cell differentiation or apoptosis. The present review focuses on recent insights into the mechanisms by which HDACIs exert their anticancer effects, either alone or in combination with other compounds, as well as attempts to translate these findings into the clinic.

1 January 2010
Verified
Journal Article
Closed access
RRRoberto R Rosato
Roberto R Rosato